

Robert DeBernardo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4483228/publications.pdf>

Version: 2024-02-01

24
papers

395
citations

933447

10
h-index

752698

20
g-index

24
all docs

24
docs citations

24
times ranked

593
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 165, 90-96.	1.4	3
2	Assessment of travel distance for hyperthermic intraperitoneal chemotherapy in women with ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100951.	0.6	2
3	Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2021, 50, 101844.	1.3	5
4	Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 45-50.	1.4	12
5	Impact of intra-operative factors upon peri-operative outcomes in women undergoing hyperthermic intraperitoneal chemotherapy for gynecologic cancer. <i>Gynecologic Oncology</i> , 2021, 161, 194-201.	1.4	8
6	Pretreatment with LCK inhibitors chemosensitizes cisplatin-resistant endometrioid ovarian tumors. <i>Journal of Ovarian Research</i> , 2021, 14, 55.	3.0	8
7	Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Gynecologic Oncology</i> , 2021, 161, 389-395.	1.4	11
8	Perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in elderly women with epithelial ovarian cancer: analysis of a prospective registry. <i>International Journal of Gynecological Cancer</i> , 2021, 31, ijgc-2021-002622.	2.5	4
9	Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Gynecologic Oncology</i> , 2021, 162, 368-374.	1.4	13
10	Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100840.	0.6	4
11	Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer. <i>Gynecologic Oncology</i> , 2021, 162, 645-651.	1.4	8
12	Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma. <i>Gynecologic Oncology</i> , 2021, 163, 511-516.	1.4	0
13	Efficacy of hyperthermic intraperitoneal chemotherapy and interval debulking surgery in women with advanced uterine serous carcinoma. <i>Gynecologic Oncology Reports</i> , 2021, 38, 100876.	0.6	2
14	Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 699-705.	1.4	15
15	Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 158, 309-315.	1.4	4
16	A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology. <i>Gynecologic Oncology</i> , 2020, 158, 794-802.	1.4	21
17	Use of prophylactic closed incision negative pressure therapy is associated with reduced surgical site infections in gynecologic oncology patients undergoing laparotomy. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 731.e1-731.e9.	1.3	10
18	Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e93.	2.2	7

#	ARTICLE	IF	CITATIONS
19	Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response. <i>Npj Precision Oncology</i> , 2018, 2, 14.	5.4	22
20	CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors. <i>Journal of Experimental Medicine</i> , 2017, 214, 2715-2732.	8.5	67
21	Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?. <i>Gynecologic Oncology</i> , 2017, 147, 85-91.	1.4	74
22	Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma. <i>Journal of Surgical Oncology</i> , 2015, 112, 188-194.	1.7	15
23	Predictors of Surgical Site Infection in Women Undergoing Hysterectomy for Benign Gynecologic Disease: A Multicenter Analysis Using the National Surgical Quality Improvement Program Data. <i>Journal of Minimally Invasive Gynecology</i> , 2014, 21, 901-909.	0.6	80
24	Cyberknife radiotherapy and anastrozole for the treatment of advanced progressive low-grade papillary serous ovarian carcinoma: A case report. <i>Gynecologic Oncology Case Reports</i> , 2013, 6, 42-44.	0.9	0